TY - JOUR AB - The study objective was to evaluate the sensitivity and specificity as well as the positive predictive value and negative predictive value of CA 72.4 and CA 125 determination, separately and in combination, for diagnosing ovarian tumors in post-menopausal women with pelvic mass. The 299 patients recruited in this study underwent gynecological examination, plasma determination of CA 72.4 and CA 125, and laparotomy with histological definition of pelvic mass. CA 72.4 assay values were under 3.9 U/ml in 194 cases (70.8%); values ranged from 3.9 to 4.5 U/ml in 7 cases (2.5%) and were greater than 4.5 U/ml in 73 cases (26.6%). CA 72.4 assay was positive (>4.5 U/ml) in 56 cases (57.1%) of malignant ovarian pathology, in 4 cases (25%) of malignant extra-ovarian pathology as well as in 9 cases (7.1%) of benign ovarian pathology and in 4 cases (11.8%) of benign extra-ovarian pathology. With a cut-off at 3.9 U/ml, CA 72.4 showed a specificity of 91.3% and a sensitivity of 62.2%, whereas with a cut-off at 4.5 U/ml specificity was 92.9% and sensitivity 57.1%. Results of CA 125 assay for diagnosing a pelvic neoplasia (ovarian or extra-ovarian), showed a specificity of 85.3% and sensitivity of 68.8%. The agreement of the two markers (CA 125 and CA 72.4) as negative or positive shows a specificity of 77% and a sensitivity of 84.7% for ovarian cancer and a specificity of 73.5% and sensitivity of 75% for the diagnosis of pelvic neoplasias. AD - UNIV PISA,OSPED S CHIARA,INST GYNEC OBSTET,I-56100 PISA,ITALY. UNIV BARI,POLICLIN,INST GYNEC OBSTET,I-70124 BARI,ITALY. UNIV BRESCIA,DEPT GYNECOL ONCOL,I-25100 BRESCIA,ITALY. OSPED SAN GERARDO,INST GYNEC OBSTET,I-20052 MONZA,ITALY. AU - MAGGINO,T AU - GADDUCCI,A AU - DADDARIO,V AU - PECORELLI,S AU - LISSONI,A AU - STELLA,M AU - ROMAGNOLO,C AU - FERDEGHINI,M AU - ZUCCA,S AU - TRIO,D AU - TROVO,S DA - 1995/11/01 DO - 10.3892/or.2.6.1069 EP - 1074 IS - 6 JO - Oncol Rep PY - 1995 SN - 1021-335X 1791-2431 SP - 1069 ST - PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS T2 - Oncology Reports TI - PROSPECTIVE MULTICENTER STUDY ON THE CLINICAL UTILITY OF CA-72.4 IN POSTMENOPAUSAL PATIENTS WITH PELVIC MASS UR - https://doi.org/10.3892/or.2.6.1069 VL - 2 ER -